WO2005051302A2 - Bicyclic inhibitors of mek and methods of use thereof - Google Patents
Bicyclic inhibitors of mek and methods of use thereof Download PDFInfo
- Publication number
- WO2005051302A2 WO2005051302A2 PCT/US2004/039061 US2004039061W WO2005051302A2 WO 2005051302 A2 WO2005051302 A2 WO 2005051302A2 US 2004039061 W US2004039061 W US 2004039061W WO 2005051302 A2 WO2005051302 A2 WO 2005051302A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heteroaryl
- aryl
- halogen
- alkyl
- cycloalkyl
- Prior art date
Links
- 0 C*Cc(cc(*)cc1)c1Nc(c(C(OC)=O)c1)c(*)c(F)c1C(C**)=O Chemical compound C*Cc(cc(*)cc1)c1Nc(c(C(OC)=O)c1)c(*)c(F)c1C(C**)=O 0.000 description 4
- NLSLBIYQHIMFOW-UHFFFAOYSA-N Nc1nnc(-c(c(Nc(c(F)c2)ccc2Br)c(c2nnc3)F)cc2c3N)[o]1 Chemical compound Nc1nnc(-c(c(Nc(c(F)c2)ccc2Br)c(c2nnc3)F)cc2c3N)[o]1 NLSLBIYQHIMFOW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04811728A EP1689233B1 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek |
AU2004293019A AU2004293019B2 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of MEK and methods of use thereof |
CA002546353A CA2546353A1 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek and methods of use thereof |
PL04811728T PL1689233T3 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek |
ES04811728T ES2389628T3 (en) | 2003-11-19 | 2004-11-18 | MEK bicyclic inhibitors |
SI200431934T SI1689233T1 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek |
JP2006541582A JP4768628B2 (en) | 2003-11-19 | 2004-11-18 | MEK bicyclic inhibitors and methods of use thereof |
DK04811728.7T DK1689233T3 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of MEK |
HK06109819.4A HK1089628A1 (en) | 2003-11-19 | 2006-09-04 | Bicyclic inhibitors of mek |
AU2011200276A AU2011200276A1 (en) | 2003-11-19 | 2011-01-24 | Bicyclic inhibitors of MEK and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52327003P | 2003-11-19 | 2003-11-19 | |
US60/523,270 | 2003-11-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005051302A2 true WO2005051302A2 (en) | 2005-06-09 |
WO2005051302A3 WO2005051302A3 (en) | 2005-08-11 |
Family
ID=34632766
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/039053 WO2005051906A2 (en) | 2003-11-19 | 2004-11-18 | Heterocyclic inhibitors of mek and methods of use thereof |
PCT/US2004/039060 WO2005051301A2 (en) | 2003-11-19 | 2004-11-18 | Heterocyclic inhibitors of mek and methods of use thereof |
PCT/US2004/039059 WO2005051300A2 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek and methods of use thereof |
PCT/US2004/039061 WO2005051302A2 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek and methods of use thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/039053 WO2005051906A2 (en) | 2003-11-19 | 2004-11-18 | Heterocyclic inhibitors of mek and methods of use thereof |
PCT/US2004/039060 WO2005051301A2 (en) | 2003-11-19 | 2004-11-18 | Heterocyclic inhibitors of mek and methods of use thereof |
PCT/US2004/039059 WO2005051300A2 (en) | 2003-11-19 | 2004-11-18 | Bicyclic inhibitors of mek and methods of use thereof |
Country Status (30)
Country | Link |
---|---|
US (7) | US7598383B2 (en) |
EP (5) | EP1689387B1 (en) |
JP (8) | JP5046649B2 (en) |
KR (3) | KR101099849B1 (en) |
CN (2) | CN102633716A (en) |
AT (2) | ATE524443T1 (en) |
AU (6) | AU2004293019B2 (en) |
BR (1) | BRPI0416692A (en) |
CA (4) | CA2545660C (en) |
CY (2) | CY1111155T1 (en) |
DE (1) | DE602004031037D1 (en) |
DK (2) | DK1689233T3 (en) |
EG (1) | EG24928A (en) |
ES (4) | ES2355797T7 (en) |
HK (4) | HK1089628A1 (en) |
HR (1) | HRP20110105T4 (en) |
IL (3) | IL175716A (en) |
MX (1) | MXPA06005657A (en) |
NO (1) | NO20062692L (en) |
NZ (1) | NZ547481A (en) |
PL (4) | PL1682138T6 (en) |
PT (4) | PT1689387E (en) |
RS (2) | RS51861B2 (en) |
RU (1) | RU2351593C2 (en) |
SG (1) | SG149033A1 (en) |
SI (1) | SI1682138T1 (en) |
TW (7) | TW201238951A (en) |
UA (1) | UA84175C2 (en) |
WO (4) | WO2005051906A2 (en) |
ZA (2) | ZA200604580B (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425556B2 (en) | 2005-12-20 | 2008-09-16 | Astrazeneca Ab | Compounds and uses thereof |
US7465795B2 (en) | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
JP2010516698A (en) * | 2007-01-19 | 2010-05-20 | アルデア バイオサイエンシズ,インコーポレイティド | MEK inhibitor |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US7803839B2 (en) | 2005-10-07 | 2010-09-28 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8030317B2 (en) | 2006-12-20 | 2011-10-04 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
US8063066B2 (en) | 2007-03-19 | 2011-11-22 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
US8394822B2 (en) | 2006-01-31 | 2013-03-12 | Ucb Pharma, S.A. | Thieno-pyridine derivatives as MEK inhibitors |
WO2013107283A1 (en) | 2012-01-17 | 2013-07-25 | Tianjin Binjiang Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US9827237B2 (en) | 2013-07-05 | 2017-11-28 | Abivax | Compounds useful for treating diseases caused by retroviruses |
US9908869B2 (en) | 2009-06-12 | 2018-03-06 | Abivax | Compounds useful for treating aids |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020261156A1 (en) | 2019-06-28 | 2020-12-30 | Array Biopharma Inc. | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
US11441181B2 (en) | 2013-01-17 | 2022-09-13 | Abivax | miRNA-124 as a biomarker |
US11649210B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
US11691973B2 (en) | 2021-03-31 | 2023-07-04 | Pfizer Inc. | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
BRPI0416692A (en) | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | heterocyclic mek inhibitors and methods of using these |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
JP2008520615A (en) * | 2004-11-24 | 2008-06-19 | ラボラトワール セローノ ソシエテ アノニム | Novel 4-arylaminopyridone derivatives as MEK inhibitors for treating hyperproliferative disorders |
AU2006237920A1 (en) * | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
KR20080023680A (en) | 2005-05-10 | 2008-03-14 | 인터뮨, 인크. | Pyridone derivatives for modulating stress-activated protein kinase system |
BRPI0610139A2 (en) * | 2005-05-18 | 2010-06-01 | Array Biopharma Inc | heterocyclic mek inhibitors and methods of using them |
JP2009528365A (en) * | 2006-02-28 | 2009-08-06 | アムゲン インコーポレイティッド | Cinnoline and quinazoline derivatives as phosphodiesterase 10 inhibitors |
DE602007009663D1 (en) * | 2006-04-18 | 2010-11-18 | Ardea Biosciences Inc | PYRIDONE SULPHONAMIDES AND PYRIDENESULFAMIDES AS MEK INHIBITORS |
WO2007123939A2 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
BRPI0711625A2 (en) | 2006-04-19 | 2011-12-06 | Serono Lab | heteroaryl substituted arylaminopyridine derivatives as mek inhibitors |
GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
WO2008047831A1 (en) | 2006-10-17 | 2008-04-24 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
CA2667447A1 (en) * | 2006-10-23 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
EP2535330A3 (en) | 2006-10-23 | 2012-12-26 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
CA2680583A1 (en) * | 2007-03-15 | 2008-09-25 | Schering Corporation | Pyridazinone derivatives useful as glucan synthase inhibitors |
EP2148863A1 (en) * | 2007-04-23 | 2010-02-03 | Novartis Ag | Phthalazine and isoquinoline derivatives with slp receptor modulating activities |
PE20090286A1 (en) * | 2007-05-11 | 2009-03-27 | Bayer Schering Pharma Ag | SUBSTITUTE PHENYLAMINOBENZENE DERIVATIVES USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES AND DISORDERS ASSOCIATED WITH EXTRACELLULAR KINASE ACTIVITY MEDIATED BY MITOGENES |
US20080312307A1 (en) * | 2007-05-25 | 2008-12-18 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
CA2705452C (en) | 2007-11-12 | 2016-05-31 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
EP2222675B1 (en) | 2007-12-19 | 2013-09-11 | Genentech, Inc. | 5-anilinoimidazopyridines and methods of use |
JP5710268B2 (en) * | 2007-12-19 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 8-Anilinoimidazopyridine and its use as an anti-cancer and / or anti-inflammatory agent |
NZ586575A (en) * | 2007-12-21 | 2012-03-30 | Genentech Inc | Azaindolizines and methods of use |
EP2240494B1 (en) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thieno-pyridine derivatives as mek inhibitors |
AU2009218459A1 (en) | 2008-02-28 | 2009-09-03 | Novartis Ag | Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease |
US20090246198A1 (en) * | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
US8304413B2 (en) * | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
EP3061752B1 (en) * | 2008-06-19 | 2018-02-21 | Xcovery Holding Company LLC | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
RU2509078C2 (en) | 2008-07-01 | 2014-03-10 | Дженентек, Инк. | Bicyclic heterocycles as mek kinase inhibitors |
MX2010014565A (en) * | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolone derivatives as mek kinase inhibitors and methods of use. |
ES2387474T3 (en) * | 2008-08-29 | 2012-09-24 | Amgen, Inc | Pyridazine-pyridinone compounds for the treatment of protein kinase mediated diseases |
WO2010025202A1 (en) * | 2008-08-29 | 2010-03-04 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
US8497269B2 (en) | 2008-10-10 | 2013-07-30 | Amgen Inc. | Phthalazine compounds as p38 map kinase modulators and methods of use thereof |
CA2742906A1 (en) * | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted amido phenoxybenzamides |
WO2010108652A1 (en) * | 2009-03-27 | 2010-09-30 | Ardea Biosciences Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
UA107100C2 (en) * | 2009-12-23 | 2014-11-25 | CONDENSED HETEROOROMATIC PYROLIDINONS AS SYK INHIBITORS | |
US9145419B2 (en) | 2010-04-28 | 2015-09-29 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds |
TWI507381B (en) | 2010-09-08 | 2015-11-11 | Sumitomo Chemical Co | Method for producing pyridazinone compounds and intermediate thereof |
CN102020651B (en) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor |
EP2638041B1 (en) | 2010-11-12 | 2015-07-22 | Bristol-Myers Squibb Company | Substituted azaindazole compounds |
AU2011349446C1 (en) | 2010-12-22 | 2016-01-21 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
FI20115234A0 (en) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | New pyridazinone and pyridone compounds |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
KR20140051942A (en) | 2011-07-12 | 2014-05-02 | 에프. 호프만-라 로슈 아게 | Aminomethyl quinolone compounds |
JO3115B1 (en) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | Pyridazinone Compounds and Their Use as DAAO Inhibitors |
CN102358730A (en) * | 2011-08-24 | 2012-02-22 | 济南赛文医药技术有限公司 | Micromolecular methyl ethyl ketone (MEK) protein kinase inhibitor |
WO2013049263A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
CU24335B1 (en) | 2012-03-14 | 2018-04-03 | Lupin Ltd | PIRIDOPIRIMIDINAS REPLACED AS INHIBITORS OF THE MEK KINASE AND USEFUL FOR THE TREATMENT OF CANCER |
US9815831B2 (en) | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
CN104640545A (en) | 2012-08-17 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
CN102841094B (en) * | 2012-09-27 | 2015-01-07 | 山东阿如拉药物研究开发有限公司 | Method for determining ferrous powder content of Tibetan medicine decoction pieces in traditional Chinese medicine preparation |
EP2900223B1 (en) * | 2012-09-28 | 2017-10-25 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
AU2013328929B2 (en) | 2012-10-12 | 2018-01-04 | Exelixis, Inc. | Novel process for making compounds for use in the treatment of cancer |
TW201441193A (en) | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | Pyridone compound |
PT3808749T (en) | 2012-12-07 | 2023-06-07 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2016512815A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2015013466A (en) | 2013-03-21 | 2016-06-21 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor. |
US9556171B2 (en) | 2013-04-18 | 2017-01-31 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
HUE046727T2 (en) | 2013-12-06 | 2020-03-30 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
PL3102576T3 (en) | 2014-02-03 | 2019-12-31 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ror-gamma |
WO2015123453A1 (en) * | 2014-02-14 | 2015-08-20 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as jak inhibitors |
EP3110820B1 (en) | 2014-02-28 | 2022-04-06 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
EP3604499A1 (en) | 2014-03-04 | 2020-02-05 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
NZ764151A (en) | 2014-06-05 | 2023-12-22 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
RU2736219C2 (en) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Method of treating cancer using a combination of chk1 and atr inhibitors |
WO2016009306A1 (en) | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
UA118989C2 (en) | 2014-10-14 | 2019-04-10 | Вітае Фармасьютікалс, Інк. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
CN107429230B (en) | 2015-01-26 | 2021-11-12 | 菲特治疗公司 | Methods and compositions for inducing hematopoietic cell differentiation |
ES2930585T3 (en) | 2015-02-27 | 2022-12-19 | Nimbus Lakshmi Inc | TYK2 inhibitors and uses thereof |
MA41866A (en) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | SELF-ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY |
WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
CA3001917A1 (en) | 2015-10-16 | 2017-04-20 | Fate Therapeutics, Inc. | Platform for the induction & maintenance of ground state pluripotency |
EP3371301A4 (en) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
ES2953925T3 (en) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Genomic engineering of pluripotent cells |
CN108463458B (en) | 2015-11-20 | 2022-02-01 | 生命医药有限责任公司 | Modulators of ROR-gamma |
CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
JP2019502725A (en) | 2016-01-20 | 2019-01-31 | フェイト セラピューティクス,インコーポレイテッド | Compositions and methods for immune cell regulation in adoptive immunotherapy |
TWI757266B (en) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | Modulators of ror-gamma |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TW201811799A (en) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | Pyrazolopyrimidine compounds and uses thereof |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
CN110536890B (en) | 2017-04-26 | 2023-08-15 | 巴斯利尔药物国际股份公司 | Method for preparing furazanobenzimidazole and crystal forms thereof |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
WO2019023207A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of rorϒ |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
EP3731840A4 (en) * | 2017-12-29 | 2021-09-15 | Orfan Biotech Inc. | Glycolate oxidase inhibitors and use thereof |
JP2021515033A (en) | 2018-02-20 | 2021-06-17 | インサイト・コーポレイションIncyte Corporation | N- (Phenyl) -2- (Phenyl) Pyrimidine-4-carboxamide Derivatives and Related Compounds as HPK1 Inhibitors for Treating Cancer |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
MA52093A (en) | 2018-03-19 | 2021-01-27 | Taiho Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION CONSISTING OF SODIUM ALKYL SULPHATE |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
SG11202012930RA (en) | 2018-07-06 | 2021-01-28 | Orfan Biotech Inc | Triazole glycolate oxidase inhibitors |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
CN113473978A (en) * | 2018-11-20 | 2021-10-01 | 恩福莱克逊治疗有限公司 | Cyanoarene-aniline compounds for the treatment of skin diseases |
CN113645964A (en) * | 2018-11-20 | 2021-11-12 | 恩福莱克逊治疗有限公司 | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy |
AU2020326703A1 (en) | 2019-08-06 | 2022-02-17 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
AR121078A1 (en) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | ARILAMIDE DERIVATIVES WITH ANTI-TUMOR ACTIVITY |
EP4134081A4 (en) | 2020-04-10 | 2024-05-01 | Taiho Pharmaceutical Co Ltd | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
WO2022018875A1 (en) | 2020-07-22 | 2022-01-27 | 中外製薬株式会社 | Arylamide derivative-containing pharmaceutical composition for treating or preventing cell proliferation diseases |
IL300051A (en) * | 2020-07-22 | 2023-03-01 | Chugai Pharmaceutical Co Ltd | Composition containing arylamide derivative |
AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682932A (en) | 1970-11-23 | 1972-08-08 | Hoffmann La Roche | 2-chloro-6-hydroxynicotinic acid |
US3855675A (en) * | 1971-05-25 | 1974-12-24 | Squibb & Sons Inc | 1-(2-furanylmethyl)-1h-pyrazolo(3,4-b)pyridine-5-methanones |
DE2150772A1 (en) * | 1971-10-12 | 1973-04-19 | Cassella Farbwerke Mainkur Ag | METHOD FOR PREPARING 6-HYDROXY-2-PYRIDONE-3-CARBONIC ACID AMIDE COMPOUNDS |
DE2307169A1 (en) | 1973-02-14 | 1974-09-26 | Bayer Ag | AZO DYES |
GB1449364A (en) * | 1974-03-20 | 1976-09-15 | Lepetit Spa | Pyrrolo 3-4-b- pyridines and method for their preparation |
JPS55167221A (en) * | 1979-06-13 | 1980-12-26 | Shigeyuki Yasuda | Anticancer drug |
AT392789B (en) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | METHOD FOR PRODUCING 1-SUBSTITUTED ARYL-1,4-DIHYDRO-4-OXONAPHTHYRIDINE DERIVATIVES |
US4851535A (en) | 1985-01-23 | 1989-07-25 | Toyama Chemical Co., Ltd. | Nicotinic acid derivatives |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
FR2664687B1 (en) * | 1990-07-12 | 1992-09-25 | Giat Ind Sa | SECURITY DEVICE FOR AN AUTOMATIC WEAPON. |
GB9120773D0 (en) * | 1991-10-01 | 1991-11-13 | Ici Plc | Modified olefin polymers |
FR2687676B1 (en) * | 1992-02-24 | 1994-07-08 | Union Pharma Scient Appl | NOVEL ANGIOTENSIN II RECEPTOR ANTAGONIST POLYAZAINDENES DERIVATIVES; THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP0600831A1 (en) * | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phtalazinon derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | Triazole derivative and pharmaceutical use thereof |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (en) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | MATRIX METALLOPROTEASE INHIBITORS |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
KR100489174B1 (en) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-anilinoquinazoline derivatives |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
DE69712496T2 (en) | 1996-07-18 | 2002-08-29 | Pfizer | MATRIX METALLOPROTEASE INHIBITORS BASED ON PHOSPHINIC ACIDS |
KR20000068248A (en) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | Arylsulfonylamino Hydroxamic Acid Derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
PT950059E (en) | 1997-01-06 | 2004-10-29 | Pfizer | CYCLIC SULFONA DERIVATIVES |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (en) | 1997-02-11 | 2000-02-15 | Pfizer | Derivatives of arylsulfonyl hydroxamic acids |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
WO1998047899A1 (en) * | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
DE69826662T2 (en) | 1997-07-01 | 2005-02-17 | Warner-Lambert Co. Llc | 4-BROM OR 4-IOD-PHENYLAMINO-BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP4462654B2 (en) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | Video material selection device and video material selection method |
JPH11296499A (en) * | 1998-04-07 | 1999-10-29 | Fujitsu Ltd | Simulation device/method using moment method and program recording medium |
PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
WO2000020390A1 (en) * | 1998-10-07 | 2000-04-13 | Georgetown University | Monomeric and dimeric heterocycles, and therapeutic uses thereof |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
ATE292462T1 (en) | 1999-01-07 | 2005-04-15 | Warner Lambert Co | TREATMENT OF ASTHMA USING MEK INHIBITORS |
CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
JP2001055376A (en) * | 1999-01-13 | 2001-02-27 | Warner Lambert Co | Diaryl amine |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
IL144215A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
AU2482800A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
WO2000042003A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
CZ20012498A3 (en) * | 1999-01-13 | 2002-08-14 | Warner-Lambert Company | Benzoheterocyclic compounds and their use as MEK inhibitors |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
ES2208364T3 (en) | 1999-07-16 | 2004-06-16 | Warner-Lambert Company Llc | PROCEDURE TO TREAT CHRONIC PAIN USING MEK INHIBITORS. |
US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
CN1373660A (en) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | Method for treating chronic pain using MEK inhibitors |
KR20020015376A (en) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Method for Treating Chronic Pain Using MEK Inhibitors |
IL147617A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
MXPA02008103A (en) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | 5 amide substituted diarylamines as mex inhibitors. |
WO2001072749A1 (en) * | 2000-03-27 | 2001-10-04 | Takeda Chemical Industries, Ltd. | Condensed pyrazole derivatives, process for producing the same and use thereof |
CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
EE200300015A (en) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as inhibitors of angiogenesis |
IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
BRPI0112584B8 (en) | 2000-07-19 | 2021-05-25 | Warner Lambert Co | Oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical composition and combination |
RU2167659C1 (en) * | 2000-08-02 | 2001-05-27 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Method of correction of immune system of living body |
PL360699A1 (en) | 2000-08-25 | 2004-09-20 | Warner-Lambert Company Llc. | Process for making n-aryl-anthranilic acids and their derivatives |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
US6642215B2 (en) | 2001-05-24 | 2003-11-04 | Leo Pharma A/S | Method of modulating NF-kB activity |
US20040039208A1 (en) | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
US20030073692A1 (en) * | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
DE60229267D1 (en) * | 2001-08-10 | 2008-11-20 | Ucb Pharma Sa | OXOPYRROLIDINE COMPOUNDS, METHOD FOR PRODUCING THESE COMPOUNDS AND THEIR USE FOR THE PRODUCTION OF LEVETIRACETAM AND ANALOGUE |
AU2002342051B2 (en) * | 2001-10-12 | 2009-06-11 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003062191A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
CN100383124C (en) | 2002-02-04 | 2008-04-23 | 霍夫曼-拉罗奇有限公司 | Quinoline derivatives as NPY antagonists |
ES2334990T3 (en) * | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | PIRIDINONES REPLACED AS MODULATORS OF P38 MAP QUINASA. |
EP2130536B1 (en) | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
RU2300528C2 (en) | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-alkylated benzimidazole derivatives as mek inhibitors |
MXPA04008822A (en) | 2002-03-14 | 2004-11-26 | Bayer Healthcare Ag | Monocyclic aroylpyridinones as antiinflammatory agents. |
CA2480638C (en) * | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
AU2003250844A1 (en) | 2002-06-24 | 2004-01-06 | Fagerdala Deutschland Gmbh | Method for producing parts from high-grade lignocellulose fiber-filled thermoplastics |
WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
BRPI0416692A (en) | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | heterocyclic mek inhibitors and methods of using these |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
ES2251866B1 (en) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
BRPI0610139A2 (en) * | 2005-05-18 | 2010-06-01 | Array Biopharma Inc | heterocyclic mek inhibitors and methods of using them |
-
2004
- 2004-11-18 BR BRPI0416692-2A patent/BRPI0416692A/en not_active IP Right Cessation
- 2004-11-18 US US10/992,612 patent/US7598383B2/en active Active
- 2004-11-18 EP EP04811726A patent/EP1689387B1/en not_active Not-in-force
- 2004-11-18 AU AU2004293019A patent/AU2004293019B2/en not_active Ceased
- 2004-11-18 AU AU2004293017A patent/AU2004293017B2/en not_active Ceased
- 2004-11-18 CA CA2545660A patent/CA2545660C/en not_active Expired - Fee Related
- 2004-11-18 RU RU2006120948/04A patent/RU2351593C2/en not_active IP Right Cessation
- 2004-11-18 PT PT04811726T patent/PT1689387E/en unknown
- 2004-11-18 AT AT04811726T patent/ATE524443T1/en active
- 2004-11-18 US US10/992,470 patent/US7485643B2/en not_active Expired - Fee Related
- 2004-11-18 SG SG200809325-4A patent/SG149033A1/en unknown
- 2004-11-18 PL PL04811727T patent/PL1682138T6/en unknown
- 2004-11-18 US US10/992,479 patent/US7576072B2/en not_active Expired - Fee Related
- 2004-11-18 SI SI200431627T patent/SI1682138T1/en unknown
- 2004-11-18 ES ES04811727T patent/ES2355797T7/en active Active
- 2004-11-18 US US10/992,605 patent/US7772234B2/en not_active Expired - Fee Related
- 2004-11-18 KR KR1020067012019A patent/KR101099849B1/en not_active IP Right Cessation
- 2004-11-18 CA CA002546353A patent/CA2546353A1/en not_active Abandoned
- 2004-11-18 WO PCT/US2004/039053 patent/WO2005051906A2/en active Application Filing
- 2004-11-18 EP EP04811727A patent/EP1682138B3/en active Active
- 2004-11-18 PL PL04811726T patent/PL1689387T3/en unknown
- 2004-11-18 WO PCT/US2004/039060 patent/WO2005051301A2/en active Application Filing
- 2004-11-18 ES ES04811728T patent/ES2389628T3/en active Active
- 2004-11-18 RS RS20110131A patent/RS51861B2/en unknown
- 2004-11-18 CA CA2545659A patent/CA2545659C/en not_active Expired - Fee Related
- 2004-11-18 PT PT04811727T patent/PT1682138E/en unknown
- 2004-11-18 CN CN2012100805779A patent/CN102633716A/en active Pending
- 2004-11-18 CN CNA2004800406607A patent/CN1905873A/en active Pending
- 2004-11-18 AU AU2004293018A patent/AU2004293018B2/en not_active Ceased
- 2004-11-18 KR KR1020127009360A patent/KR101264570B1/en not_active IP Right Cessation
- 2004-11-18 MX MXPA06005657A patent/MXPA06005657A/en active IP Right Grant
- 2004-11-18 PL PL10008429T patent/PL2251327T3/en unknown
- 2004-11-18 PT PT100084292T patent/PT2251327E/en unknown
- 2004-11-18 WO PCT/US2004/039059 patent/WO2005051300A2/en active Application Filing
- 2004-11-18 ES ES10008429.2T patent/ES2453367T3/en active Active
- 2004-11-18 ZA ZA200604580A patent/ZA200604580B/en unknown
- 2004-11-18 AU AU2004293436A patent/AU2004293436B2/en not_active Ceased
- 2004-11-18 JP JP2006541580A patent/JP5046649B2/en not_active Expired - Fee Related
- 2004-11-18 DK DK04811728.7T patent/DK1689233T3/en active
- 2004-11-18 PT PT04811728T patent/PT1689233E/en unknown
- 2004-11-18 JP JP2006541582A patent/JP4768628B2/en not_active Expired - Fee Related
- 2004-11-18 JP JP2006541579A patent/JP4842137B2/en not_active Expired - Fee Related
- 2004-11-18 EP EP04811728A patent/EP1689233B1/en not_active Not-in-force
- 2004-11-18 UA UAA200606021A patent/UA84175C2/en unknown
- 2004-11-18 ES ES04811726T patent/ES2369835T3/en active Active
- 2004-11-18 WO PCT/US2004/039061 patent/WO2005051302A2/en active Application Filing
- 2004-11-18 RS RS20110131A patent/RS51861B/en unknown
- 2004-11-18 DK DK04811727.9T patent/DK1682138T3/en active
- 2004-11-18 KR KR1020117021608A patent/KR101190912B1/en not_active IP Right Cessation
- 2004-11-18 AT AT04811727T patent/ATE495155T1/en active
- 2004-11-18 EP EP10008429.2A patent/EP2251327B1/en active Active
- 2004-11-18 JP JP2006541581A patent/JP4869075B2/en not_active Expired - Fee Related
- 2004-11-18 NZ NZ547481A patent/NZ547481A/en not_active IP Right Cessation
- 2004-11-18 CA CA002546486A patent/CA2546486A1/en not_active Abandoned
- 2004-11-18 EP EP04811721A patent/EP1689406A4/en not_active Withdrawn
- 2004-11-18 DE DE602004031037T patent/DE602004031037D1/en active Active
- 2004-11-18 PL PL04811728T patent/PL1689233T3/en unknown
- 2004-11-19 TW TW101112592A patent/TW201238951A/en unknown
- 2004-11-19 TW TW101112591A patent/TW201242950A/en unknown
- 2004-11-19 TW TW093135614A patent/TW200529852A/en unknown
- 2004-11-19 TW TW093135612A patent/TW200526594A/en unknown
- 2004-11-19 TW TW100103289A patent/TW201118071A/en unknown
- 2004-11-19 TW TW093135618A patent/TW200526658A/en unknown
- 2004-11-19 TW TW093135622A patent/TWI404703B/en not_active IP Right Cessation
-
2006
- 2006-05-17 IL IL175716A patent/IL175716A/en not_active IP Right Cessation
- 2006-05-18 EG EGNA2006000472 patent/EG24928A/en active
- 2006-06-12 NO NO20062692A patent/NO20062692L/en unknown
- 2006-09-04 HK HK06109819.4A patent/HK1089628A1/en not_active IP Right Cessation
- 2006-09-04 HK HK06109818.5A patent/HK1089659A1/en not_active IP Right Cessation
- 2006-09-12 HK HK06110118.0A patent/HK1092684A1/en not_active IP Right Cessation
-
2008
- 2008-09-04 ZA ZA2008/07628A patent/ZA200807628B/en unknown
-
2009
- 2009-01-20 US US12/356,428 patent/US8211921B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/356,441 patent/US8431574B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/356,415 patent/US8268852B2/en not_active Expired - Fee Related
-
2010
- 2010-05-18 AU AU2010201987A patent/AU2010201987A1/en not_active Abandoned
-
2011
- 2011-01-24 AU AU2011200276A patent/AU2011200276A1/en not_active Abandoned
- 2011-01-31 CY CY20111100098T patent/CY1111155T1/en unknown
- 2011-02-10 JP JP2011026680A patent/JP2011121984A/en active Pending
- 2011-02-11 HR HRP20110105TT patent/HRP20110105T4/en unknown
- 2011-03-28 JP JP2011070629A patent/JP2011173890A/en active Pending
- 2011-03-28 JP JP2011070628A patent/JP2011153151A/en active Pending
- 2011-05-13 HK HK11104718.0A patent/HK1150607A1/en not_active IP Right Cessation
- 2011-11-17 IL IL216454A patent/IL216454A0/en unknown
- 2011-11-17 IL IL216455A patent/IL216455A0/en unknown
-
2012
- 2012-02-14 JP JP2012029242A patent/JP2012092151A/en active Pending
- 2012-07-25 CY CY20121100662T patent/CY1112941T1/en unknown
Non-Patent Citations (1)
Title |
---|
See references of EP1689233A4 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US11597699B2 (en) | 2005-10-07 | 2023-03-07 | Exelixis, Inc. | MEK inhibitors and methods of their use |
AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7803839B2 (en) | 2005-10-07 | 2010-09-28 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7915250B2 (en) | 2005-10-07 | 2011-03-29 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
CN109053523A (en) * | 2005-10-07 | 2018-12-21 | 埃克塞利希斯股份有限公司 | Azetidine as the mek inhibitor for treating proliferative disease |
US8362002B2 (en) | 2005-10-07 | 2013-01-29 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7465795B2 (en) | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
US7425556B2 (en) | 2005-12-20 | 2008-09-16 | Astrazeneca Ab | Compounds and uses thereof |
US8394822B2 (en) | 2006-01-31 | 2013-03-12 | Ucb Pharma, S.A. | Thieno-pyridine derivatives as MEK inhibitors |
US8604051B2 (en) | 2006-01-31 | 2013-12-10 | Ucb Pharma S.A. | Thieno-pyridine derivatives as MEK inhibitors |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
US8470837B2 (en) | 2006-12-20 | 2013-06-25 | Takeda Pharmaceutical Company Limted | MAPK/ERK kinase inhibitors |
US8030317B2 (en) | 2006-12-20 | 2011-10-04 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
US7820664B2 (en) | 2007-01-19 | 2010-10-26 | Bayer Schering Pharma Ag | Inhibitors of MEK |
US8063049B2 (en) | 2007-01-19 | 2011-11-22 | Ardea Biosciences, Inc. | Inhibitors of MEK |
JP2010516698A (en) * | 2007-01-19 | 2010-05-20 | アルデア バイオサイエンシズ,インコーポレイティド | MEK inhibitor |
US8063066B2 (en) | 2007-03-19 | 2011-11-22 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
US11014918B2 (en) | 2009-06-12 | 2021-05-25 | Abivax | Compounds and pharmaceutical compositions containing at least one of the compounds |
US10683284B2 (en) | 2009-06-12 | 2020-06-16 | Abivax | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging |
US10975063B2 (en) | 2009-06-12 | 2021-04-13 | Abivax | Compound, and production method thereof, and methods of treatment using the compound |
KR101863021B1 (en) * | 2009-06-12 | 2018-05-30 | 아비박스 | Compounds useful for treating cancer |
EP3521283A1 (en) * | 2009-06-12 | 2019-08-07 | Abivax | Compounds useful for treating cancer |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
US9908869B2 (en) | 2009-06-12 | 2018-03-06 | Abivax | Compounds useful for treating aids |
US10017498B2 (en) | 2009-06-12 | 2018-07-10 | Abivax | Compounds useful for treating AIDS |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
US9279144B2 (en) | 2010-02-25 | 2016-03-08 | Dana-Farber Cancer Institute, Inc. | Screening method for BRAF inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
US9290468B2 (en) | 2012-01-17 | 2016-03-22 | Shanghai Kechow Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
US9937158B2 (en) | 2012-01-17 | 2018-04-10 | Shanghai Kechow Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013107283A1 (en) | 2012-01-17 | 2013-07-25 | Tianjin Binjiang Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
US11441181B2 (en) | 2013-01-17 | 2022-09-13 | Abivax | miRNA-124 as a biomarker |
US9827237B2 (en) | 2013-07-05 | 2017-11-28 | Abivax | Compounds useful for treating diseases caused by retroviruses |
US11649211B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
US11649210B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020261156A1 (en) | 2019-06-28 | 2020-12-30 | Array Biopharma Inc. | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
US11691973B2 (en) | 2021-03-31 | 2023-07-04 | Pfizer Inc. | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors |
US11802127B2 (en) | 2021-03-31 | 2023-10-31 | Pfizer Inc. | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1689233B1 (en) | Bicyclic inhibitors of mek | |
US8211920B2 (en) | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006541582 Country of ref document: JP Ref document number: 2546353 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004293019 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004811728 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004293019 Country of ref document: AU Date of ref document: 20041118 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004293019 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004811728 Country of ref document: EP |